About OXGENE
OXGENE is a company based in Oxford (United Kingdom) founded in 2011 was acquired by WuXi AppTec in March 2021. OXGENE has raised $28.09 million across 13 funding rounds from investors including Gov.uk, WuXi AppTec and Canaccord Genuity Group. The company has 102 employees. OXGENE operates in a competitive market with competitors including Inscripta, Poseida Therapeutics, Senti Biosciences, GenScript and ADARx Pharmaceuticals, among others.
- Headquarter Oxford, United Kingdom
- Employees 102
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website oxgene.com
- Social LinkedIn X Facebook
- Acquired by WuXi AppTec (Mar 2021)
- Legal Name Oxford Genetics Ltd
- Date of Incorporation 28 Apr, 2011
- Jurisdiction OXFORD, UNITED KINGDOM
- Annual Revenue$110.6 K (USD)-35as on Dec 31, 2023
- Net Profit-$43.65 K (USD)-257as on Dec 31, 2023
- EBITDA-$42.48 K (USD)-309as on Dec 31, 2023
- Total Equity Funding$28.09M (USD)
in 13 rounds
- Latest Funding Round$1.02M (USD), Series A
Jul 2025
- InvestorsGov.uk
& 4 more
- Employee Count102
- Acquired byWuXi AppTec
(Mar 2021)
Funding Insights of OXGENE
OXGENE has successfully raised a total of $28.09M across 13 strategic funding rounds. The most recent funding activity was a Series A round of $1.02 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.09M
- Total Rounds 13
- Last Round Series A — $1.02M
- First Round $72,185
(Jun 2011)
- Investors Count 4
Latest 10 of 13 funding rounds of OXGENE with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $1.02M | Series A | – | – | |
| May 2020 | $3.74M | Series A | – | Mercia, Canaccord Genuity Group | – |
| Mar 2019 | $8.59M | Series A | – | Mercia, Canaccord Genuity Group | – |
| Aug 2017 | $10.3M | Series A | – | Mercia, Invesco | – |
| Jun 2017 | $644,510 | Seed | – | Mercia | – |
| Dec 2016 | $2.04M | Grant | – | – | |
| Mar 2016 | $2.6M | Seed | – | – | – |
| Jun 2015 | $457,000 | Seed | – | – | – |
| Jul 2014 | $169,632 | Grant | – | – | |
| Mar 2014 | $443,000 | Seed | – | – | – |
5 investors in total: 5 institutional.
Investors in OXGENE
OXGENE has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Gov.uk, WuXi AppTec and Canaccord Genuity Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment management services are provided by Mercia to various clients. | 1982 | mercia.co.uk | - | |
Merger and acquisitions advisory firm | 1950 | canaccordgenuity.com | Toronto, Canada | |
Diversified asset management services are offered globally by Invesco. | – | invesco.com | Atlanta, United States | |
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom | |
Provider of CRO and CDMO services | 2000 | wuxiapptec.com | Shanghai, China |
Investor details for OXGENE
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of OXGENE
3 people are tracked at OXGENE (2 in leadership, 1 in team); the tracked headcount is 102.
| Name | Role | Group |
|---|---|---|
Martin Hall | Finance Director | Leadership |
Len Seymour | Founding Scientist And Non Executive Director | Leadership |
Aleksander M. | IT Systems Administrator | Team |
Complete people profiles for OXGENE
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of OXGENE
4 dated milestones of OXGENE across 14 years, from founding to its latest funding, stage changes and deals.
- Founded OXGENE is founded.
- Funding First funding round of $72K.
- Exit Acquired by WuXi AppTec.
- Funding Latest funding round, Series A, of $1.0M.
Competitors of OXGENE
OXGENE operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inscripta, Poseida Therapeutics, Senti Biosciences, GenScript and ADARx Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| inscripta.io | 2015 | Helsinki, Finland | $853,384 | – | Speech recognition solutions are provided by Inscripta for healthcare professionals. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| sentibio.com | 2016 | San Francisco, United States | $158M | – | Cell-based therapies for cancer treatment are developed. | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| adarx.com | 2019 | San Diego, United States | $352.5M | 44 | Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts | |
| oncodna.com | 2012 | Charleroi, Belgium | $44.53M | 37 | Genomic and theranostic services for oncology precision medicine are delivered. | |
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| crisprtx.com | 2013 | Basel, Switzerland | $127M | – | Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | |
| miltenyibiotec.com | 1989 | Bergisch Gladbach, Germany | – | 585 | Develops tools and products for research and clinical application | |
| diagenode.com | 2003 | Seraing, Belgium | $8.45M | 99 | Reagents and kits for epigenetics sequencing solutions are developed. |
Detailed competitors of OXGENE
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OXGENE
Websites that share an audience with OXGENE (oxgene.com).
Websites whose visitors overlap most with OXGENE. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| horizondiscovery.com | 100% | 63.5K | #524,580 | View details |
Latest news on Oxgene
Complete news archive for OXGENE
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OXGENE
10 companies that operate in the same segment as OXGENE (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OXGENE
OXGENE was founded in 2011.
OXGENE is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
OXGENE is a funded company, having raised a total of $28.09M across 13 funding rounds to date. The company's 1st funding round was a Seed of $443K, raised on Jun 2011.
OXGENE has 102 employees.
Annual revenue of OXGENE is $110.6K as on Dec 31, 2023.
OXGENE was founded in 2011 in Oxford, United Kingdom, and operates in the biotechnology sector. A platform for mammalian cell engineering is offered, along with plasmid and DNA component products and SnapFast plasmid technology. DNA sequences are designed, protein expression is optimized, cell lines are developed, and viral delivery systems are improved. Bioinformatics and gene-editing technologies are integrated to support streamlined workflows for cell line production.
OXGENE's top competitors include CRISPR Therapeutics, Senti Biosciences and Poseida Therapeutics.
OXGENE has 5 investors. Key investors include Gov.uk, WuXi AppTec, Canaccord Genuity Group, Mercia, and Invesco.
OXGENE operates through Oxford Genetics Ltd.
Yes. OXGENE was acquired by WuXi AppTec in March 2021.